INSTITUTUL REGIONAL DE ONCOLOGIE IASI

Their core work

The Regional Institute of Oncology Iasi (IRO Iasi) is Romania's main oncology hospital and research centre in the north-east of the country, combining cancer patient care with clinical and translational research. Their H2020 work centres on advanced colorectal cancer therapy and on building institutional capacity for interdisciplinary biomedical research, including nanomedicine and AI-based clinical decision support. They act both as a clinical partner contributing patient cohorts and oncology expertise to European research, and as a capacity-building hub trying to raise biomedical research quality in Romania.

What they specialise in

How they've shifted over time

Their first H2020 engagement (REVERT, 2020) was clinical and disease-specific: colorectal cancer therapy supported by a computational/AI framework. By 2021 they had moved into the coordinator seat with ESEI-BioMed, broadening their profile from a single cancer indication toward interdisciplinary biomedical research in general, with a clear pivot toward nanomedicine, nano(bio)sensors and nanodrugs. The trajectory is from clinical-trial participant to ambition to become a regional biomedical research hub.

They are positioning themselves as the biomedical research anchor for north-east Romania, with growing interest in nanomedicine and AI-enabled oncology — relevant for partners needing a Romanian clinical site plus emerging nano/AI capabilities.

How they like to work

They have played both roles: joining a larger European consortium as a clinical partner in REVERT, and stepping up to coordinate the Widening CSA ESEI-BioMed. Across the two projects they have worked with 22 distinct partners in 6 countries, which for a two-project footprint suggests they engage with sizeable consortia rather than tight bilateral collaborations. Working with them typically means access to a Romanian oncology hospital and, through ESEI-BioMed, to the TRANSCEND biomedical research centre they are building around it.

Small but diverse network: 22 unique partners across 6 countries from just two projects, indicating broad European reach rather than a local cluster. No single dominant geography beyond their Romanian base in Iasi.

What sets them apart

They are one of the few Romanian oncology institutes acting as a full H2020 coordinator, which is unusual in a Widening country. The combination of an operating cancer hospital with a CSA-funded capacity programme (ESEI-BioMed / TRANSCEND) means partners get both clinical access and a deliberately built research infrastructure in one place. For consortia that need a Romanian clinical site, access to oncology patients, or a Widening partner with real coordinator experience, they are a stronger choice than a typical university department.

Highlights from their portfolio

• ESEI-BioMed
  Their largest project and a coordinator role, EUR 2.5M CSA to build interdisciplinary biomedical research excellence — signals institutional ambition beyond clinical care.
• REVERT
  Clinical-research contribution to an AI-based decision support system for advanced colorectal cancer, combining molecular mechanisms, predictive models and a shared database.